Header Logo

Connection

IRINA AGOULNIK to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications IRINA AGOULNIK has written about Prostatic Neoplasms.
IRINA AGOULNIK
Connection Strength
2.529
Prostatic Neoplasms
  1. Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells. Sci Rep. 2020 03 02; 10(1):3836.
    View in: PubMed
    Score: 0.361
  2. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.326
  3. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.274
  4. INPP4B suppresses prostate cancer cell invasion. Cell Commun Signal. 2014 Sep 25; 12:61.
    View in: PubMed
    Score: 0.247
  5. Androgen receptor footprint on the way to prostate cancer progression. World J Urol. 2012 Jun; 30(3):279-85.
    View in: PubMed
    Score: 0.201
  6. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.191
  7. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.155
  8. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.143
  9. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.142
  10. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.132
  11. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.055
  12. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 2010 Dec; 17(4):1021-33.
    View in: PubMed
    Score: 0.047
  13. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 2009 Apr; 1160:379-80.
    View in: PubMed
    Score: 0.042
  14. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.042
  15. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.041
  16. Relaxin promotes prostate cancer progression. Clin Cancer Res. 2007 Mar 15; 13(6):1695-702.
    View in: PubMed
    Score: 0.037
  17. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.033
  18. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.033
  19. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.